Curated News
By: NewsRamp Editorial Staff
August 31, 2026
Quantum BioPharma's Lucid-MS Gets Buy Rating, $8 Target from Rodman & Renshaw
TLDR
- Quantum BioPharma (NASDAQ: QNTM) receives a Buy rating and $8 price target from Rodman & Renshaw, signaling potential upside for investors.
- Lucid-MS, a first-in-class non-immunomodulatory small molecule, targets neurodegeneration in progressive multiple sclerosis by preventing and reversing myelin degradation.
- Quantum BioPharma's Lucid-MS aims to address limited treatment options for progressive MS, potentially improving the lives of patients with this challenging condition.
- Quantum BioPharma retains a 19.48% stake in Unbuzzd Wellness and earns royalties on UNBUZZD sales, with a 7% rate until $250 million, then 3% forever.
Impact - Why it Matters
This news matters because it brings attention to a potentially groundbreaking treatment for progressive multiple sclerosis, a condition with limited therapeutic options. The 'Buy' rating and price target from a reputable analyst firm like Rodman & Renshaw may boost investor confidence and funding for Quantum BioPharma, accelerating the development of Lucid-MS. If successful, Lucid-MS could offer new hope for MS patients, addressing neurodegeneration and disability progression, and potentially improve quality of life for millions affected worldwide. Additionally, the commercial potential of Lucid-MS could drive significant value for shareholders, making this a key development to watch in the biotech sector.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on innovative treatments for challenging neurodegenerative, metabolic, and alcohol misuse disorders, has received a 'Buy' rating from Rodman & Renshaw, a leading investment bank. The firm initiated coverage with an $8.00 price target, highlighting the potential of Quantum's lead drug candidate, Lucid-MS. This first-in-class, non-immunomodulatory small molecule is designed to address neurodegeneration and disability progression in progressive multiple sclerosis (MS), a condition where current therapeutic options are limited. The analyst's valuation reflects the promise of Quantum's development pipeline, particularly Lucid-MS, which has shown in preclinical models to prevent and reverse myelin degradation—the underlying mechanism of MS.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is advancing Lucid-MS, a patented new chemical entity. Additionally, Quantum has spun out its OTC product, UNBUZZD(TM), to Unbuzzd Wellness Inc. (UWI), led by industry veterans, while retaining a 19.48% ownership stake (as of June 30, 2026). The agreement includes royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains full rights to develop similar pharmaceutical and medical formulations. For more information on Lucid-MS, visit https://nnw.fm/8uqwL. The latest news and updates on QNTM are available in the company's newsroom at https://nnw.fm/QNTM.
This news was disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising, as part of a broader communications strategy by NetworkNewsWire (NNW), a specialized platform focused on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release services, and social media distribution to millions of followers. This coverage aims to bring Quantum's developments to a wide audience of investors and the general public, highlighting the potential impact of Lucid-MS on the MS treatment landscape.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Gets Buy Rating, $8 Target from Rodman & Renshaw
